Chul Kim, MD,MPH| Medical Oncology, Hematology Oncology | MedStar Health

Chul Kim, MD, MPH
Provider is directly employed by MedStar Health

4.9 out of 5 (202 reviews)

Specialties: Medical Oncology, Hematology Oncology

Languages: English

(202) 444-0770

About me

Dr. Chul Kim is an Assistant Professor at Georgetown University focusing on thoracic oncology. He strives to bring novel cancer immunotherapies and targeted therapies to the clinic and devise clinical trials to develop personalized cancer treatments.

Dr. Kim graduated Summa Cum Laude from Sungkyunkwan University School of Medicine in Seoul, South Korea and obtained his Master’s degree in Public Health from Harvard School of Public Health. He received training in internal medicine at the University of Minnesota. He was a clinical fellow in hematology and oncology at the National Cancer Institute (NCI) of the National Institutes of Health (NIH). He received a Norman Rales Young Investigator Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) in 2018.

He has published more than 40 articles in peer-reviewed journals such as Lancet Oncology, JAMA Oncology, Journal of Thoracic OncologyJournal for ImmunoTherapy of Cancer, and Clinical Cancer Research. He has served as a reviewer for several journals including Journal of Clinical Oncology, Clinical Lung Cancer, Lancet HIV, Lancet Haematology, and JCO Precision Oncology. He is a member of American Society of Clinical Oncology and International Association for the Study of Lung Cancer.

His goal as an oncologist is to provide the best possible treatment for his patients.

Clinical areas of focus

  • Adenocarcinoma Of Lung
  • Biological Targeted Therapy
  • Cancer Chemotherapy
  • Cancer Immunotherapy
  • Chemoradiation
  • Lung Cancer
  • Lung Metastasis
  • Mesothelioma
  • Non Small Cell Lung Cancer
  • Pleural Cancer
  • Pulmonary Nodule
  • Small Cell Lung Cancer
  • Thymoma
  • Thymus Cancer
Show More

Conditions and procedures

Conditions I treat

  • Adenocarcinoma Of Lung
  • Lung Cancer
  • Lung Metastasis
  • Mesothelioma
  • Non Small Cell Lung Cancer
  • Pleural Cancer
  • Pulmonary Nodule
  • Small Cell Lung Cancer
  • Thymoma
  • Thymus Cancer
Show All Show Less

Procedures I perform

  • Biological Targeted Therapy
  • Cancer Chemotherapy
  • Cancer Immunotherapy
  • Chemoradiation
Show All button Press enter to expand Show Less

Practice locations

Distance from Change LocationEnter your Location

3800 Reservoir Road Northwest
Lombardi Cancer Center
Washington, DC, 20007


Fax 202-444-1229

Get Directions

miles away

Fax 202-444-1229


MedStar Medical Group accepts most major health insurance plans. If you are uncertain as to whether your individual health insurance plan is accepted at MedStar Medical Group, please call your insurance company.

  • List of insurance plans we accept
    • Aetna Elect Choice/ EPO (Aetna Health Fund) Innovation Health: Network Only Plus
    • Aetna Quality Point of Service (POS)
    • Aetna Student Health Insurance
    • Aetna Medicare Advantage HMO & PPO Plans
    • CFBCBS BlueChoice HMO
    • CFBCBS Blue Choice Opt Out Plus Open Access (POS)
    • CFBCBS Maryland Point of Service Plan (MPOS)
    • CFBCBS Maryland Indemnity or PPO
    • CFBCBS (NCA) Indemnity
    • CIGNA HMO & Network (HMO)
    • CIGNA POS/Network POS
    • Great-West Healthcare POS/CIGNA
    • CIGNA Indemnity
    • Coventry Health Care of Virginia
    • Coventry of Delaware HMO/PPO
    • First Health PPO
    • Tricare Prime
    • Tricare for Life (Medicare Supplemental Plan)
    • MedStar Family Choice - Maryland Health Choice
    • MedStar Select (MedStar Associates' Plan)
    • United Healthcare Select HMO - EPO/NPP
    • United Healthcare Select Plus (POS)
    • United Healthcare Choice Plus
    • United Student Resources
    • M.D. IPA (HMO)
    • M.D. IPA Preferred (POS)
    • Optimum Choice Preferred (POS) & OCI Direct (HMO)
    • Mamsi Life & Health (Indem./PPO)
    • Aetna Worker's Compensation Network
    • Coventry Health Care National Network PPO
    • United Healthcare Choice
    • CIGNA HMO Open Access (OA)
    • Network OA
    • POS OA & OA Plus
    • PPO and PPO Plus
    • Choice Fund PPO
    • CFBSBC Blue Preferred PPO
    • HealthyBlue PPO
    • CFBCBS Blue Choice Opt Out Open Access
    • BlueChoice Open Access
    • Aetna Traditional Choice (PPO)
    • Innovation Health: Indemnity
    • Aetna Open Choice (PPO)
    • Innovation Health: PPO
    • Aetna Managed Choice (POS)
    • Innovation Health: POS Plus
    • Aetna Elect Choice/ Open Access (POS)
    • Innovation Health: Open Network Only Plus
    • Aetna HMO-Open Access/Select OA/HealthFund/Health Network Option OA
    • Innovation Health: POS
    • Open HMO
    • Opoen HMO Option
    • Open EPO Plus
    • Aetna Managed Choice Open Access (POS)
    • Choice POS & Choice POS II
    • Innovation Health: Open POS Plus
    • Open POS II
    • Aetna HMO
    • Select HMO/HealthFund/Health Network
    • Aetna Innovations: HMO & EPO Plus
    • Blue Choice Advantage & Healthy Blue (HMO, POS)"
    • CFBCBS Federal Employee Program (Std/Basic PPO/Blue Focus)
    • Kaiser MD Medicaid MCO
    • Kaiser Permanente Flexible Choice POS
    • Kaiser Permanente Medicare Plus (Medicare Supplemental Plan)
    • Kaiser Permanente Select
    • Kaiser Permanente Signature
    • Kaiser Permanente Signature-Added Choice
    • Kaiser PermanenteSelect-Added Choice
    • Kaiser Virginia Premier
    • Medicare Fee for Service
    • Private Health Care Systems (PHCS) (PPO)
    • UHC Community Plan of MD
    • United Healthcare Options (PPO) (includes Empire PPO, GEHA, Compass Rose)"
    • UnitedHealthcare and AARP Medicare Complete Plans/ UHC Group Medicare Advantage Plans HMO, POS, PPO"
    • UnitedHealthcare Medicare Adv/Special Needs Plans
    • Kaiser Permanente Medicare Advantage Signature and Select (aka Senior Advantage)"


Board Certification: American Board of Internal Medicine, Medical Oncology

Board Certification: American Board of Internal Medicine, Hematology

Board Certification: American Board of Internal Medicine, Internal Medicine

Fellowship Program: National Cancer Institute (2017)

Residency Program: Univ. of Minnesota Hospital and Clinic (2014)

Medical School: Sungkyunkwan University School of Medicine (2007)

News and publications

Original papers in refereed journals 

1.         Tlemsani C, Takahashi N, Pongor L, Rajapakse VN, Tyagi M, Wen X, Fasaye GA, Schmidt KT, Desai P, Kim C, Rajan A, Swift S, Sciuto L, Vilimas R, Webb S, Nichols S, Figg WD, Pommier Y, Calzone K, Steinberg SM, Wei JS, Guha U, Turner CE, Khan J, Thomas A. Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. Sci Transl Med. 2021;13(578). Epub 2021/01/29. doi: 10.1126/scitranslmed.abc7488. PubMed PMID: 33504652.

2.         Peravali M, Joshi I, Ahn J, Kim C. A Systematic Review and Meta-Analysis of Clinical Characteristics and Outcomes in Patients With Lung Cancer with Coronavirus Disease 2019. JTO Clin Res Rep. 2021;2(3):100141. Epub 2021/01/14. doi: 10.1016/j.jtocrr.2020.100141. PubMed PMID: 33437971; PMCID: PMC7790456.

3.         McGunigal M, Margolis M, Forsthoefel M, Singh T, Amarell K, Deblois D, Campbell L, Kim C, Liu S, Bergquist PJ. Thymic malignancies treated with active scanning proton beam radiation and Monte Carlo planning: early clinical experience. Acta Oncologica. 2021:1-4.

4.         Kareff SA, Samtani S, Burotto M, Prasad V, Kim C. Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors. JTO Clinical and Research Reports. 2021;2(4):100149.

5.         Giaccone G, Kim C. Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up. J Thorac Oncol. 2021;16(3):483-5. Epub 2020/11/29. doi: 10.1016/j.jtho.2020.11.003. PubMed PMID: 33248322.

6.         Estrada-Bernal A, Le AT, Doak AE, Tirunagaru VG, Silva S, Bull MR, Smaill JB, Patterson AV, Kim C, Liu SV, Doebele RC. Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021;27(5):1463-75. Epub 2020/12/24. doi: 10.1158/1078-0432.CCR-20-3555. PubMed PMID: 33355298; PMCID: PMC7926264.

7.         Dudnik E, Kareff S, Moskovitz M, Kim C, Liu SV, Lobachov A, Gottfried T, Urban D, Zer A, Rotem O. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. Journal for immunotherapy of cancer. 2021;9(2).

8.         Zaemes J, Kim C. Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature. Eur J Cancer. 2020;132:168-75. Epub 2020/05/07. doi: 10.1016/j.ejca.2020.03.015. PubMed PMID: 32375103.

9.         Taylor KL, Fallon S, Subramaniam D, Davis K, To C, Lobo T, Tercyak KP, Friberg J, Tynan M, Russell E, Ahmed W, Ponder MC, Cusaac L, Thompson J, Gardner K, Kim C, Weiner LM. Implementation of the Smoking Treatment and Recovery (STAR) program: healthy cancer survivorship through integrated tobacco control. J Cancer Surviv. 2020;14(1):53-8. Epub 2019/11/07. doi: 10.1007/s11764-019-00826-1. PubMed PMID: 31686365.

10.       Roper N, Brown A-L, Wei JS, Pack S, Trindade C, Kim C, Restifo O, Gao S, Sindiri S, Mehrabadi F, Meskini RE, Ohler ZW, Maity TK, Venugopala A, Cultraro CM, Akoth E, Padiernos E, Chen H, Kesarwala A, Smart DK, Nilubol N, Rajan A, Piotrowska Z, Xi L, Raffeld M, Pachenko AR, Sahinalp C, Hewitt S, Hoang CD, Khan J, Guha U. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. Cell Reports Medicine. 2020;1(1).

11.       Peravali M, Wang H, Kim C, Veytsman I. Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Curr Oncol Rep. 2020;22(12):119. Epub 2020/09/19. doi: 10.1007/s11912-020-00981-0. PubMed PMID: 32945977.

12.       Li N, Guha U, Kim C, Ye L, Cheng J, Li F, Chia D, Wei F, Wong DT. Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports. Frontiers in oncology. 2020;10:1240.

13.       Kim C, Liu SV, Subramaniam DS, Torres T, Loda M, Esposito G, Giaccone G. Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 2020;8(2). Epub 2020/07/04. doi: 10.1136/jitc-2020-000980. PubMed PMID: 32616557; PMCID: PMC7333915.

14.       Kareff SA, Lischalk JW, Krochmal R, Kim C. Abscopal effect in pulmonary carcinoid tumor following ablative stereotactic body radiation therapy: a case report. J Med Case Rep. 2020;14(1):177. Epub 2020/10/05. doi: 10.1186/s13256-020-02512-8. PubMed PMID: 33010806; PMCID: PMC7532944.

15.       Farid S, Latif H, Nilubol C, Kim C. Immune Checkpoint Inhibitor-induced Fanconi Syndrome. Cureus. 2020;12(4):e7686. doi: 10.7759/cureus.7686.

16.       Shah NJ, Al-Shbool G, Blackburn M, Cook M, Belouali A, Liu SV, Madhavan S, He AR, Atkins MB, Gibney GT, Kim C. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer. 2019;7(1):353. Epub 2019/12/19. doi: 10.1186/s40425-019-0771-1. PubMed PMID: 31847881; PMCID: PMC6918622.

17.       Desai S, Kim C, Veytsman I. Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give? Curr Oncol Rep. 2019;21(9):84. Epub 2019/08/15. doi: 10.1007/s11912-019-0835-x. PubMed PMID: 31410582.

18.       Cook MR, Kim C. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review. JAMA Oncol. 2019;5(7):1049-54. Epub 2019/02/08. doi: 10.1001/jamaoncol.2018.6737. PubMed PMID: 30730549.

19.       Al-Shbool G, Latif H, Farid S, Wang S, Ahn J, Giaccone G, Kim C. Publication Rate and Characteristics of Lung Cancer Clinical Trials. JAMA Netw Open. 2019;2(11):e1914531. Epub 2019/11/07. doi: 10.1001/jamanetworkopen.2019.14531. PubMed PMID: 31693119; PMCID: PMC6865260.

20.       Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, Manning M, Mogg R, Blumenschein WM, Tan MT, Subramaniam DS, Liu SV, Kaplan IM, McCutcheon JN. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19(3):347-55. Epub 2018/02/06. doi: 10.1016/S1470-2045(18)30062-7. PubMed PMID: 29395863.

21.       Valle L, Thomas J, Kim C, Szabo E, Brown GT, Citrin D, Rajan A. Hepatoid adenocarcinoma of the lung metastasizing to the tonsil. Mol Clin Oncol. 2017;6(5):705-7. Epub 2017/05/23. doi: 10.3892/mco.2017.1215. PubMed PMID: 28529745; PMCID: PMC5431682.

22.       Gharwan H, Kim C, Thomas A, Berman A, Kim SA, Biassou N, Steinberg SM, Rajan A. Thymic epithelial tumors and metastasis to the brain: a case series and systematic review. Transl Lung Cancer Res. 2017;6(5):588-99. Epub 2017/11/09. doi: 10.21037/tlcr.2017.08.06. PubMed PMID: 29114474; PMCID: PMC5653528.

23.       Del Rivero J, Kim C, Eid M, Ahlman MA, Nieman LK, Rajan A. Thymic Hyperplasia after Treatment of ACTH-Dependent Cushing's Syndrome Can Be Mistaken for a Thymic Epithelial Tumor. J Thorac Oncol. 2017;12(4):e29-e32. Epub 2016/11/21. doi: 10.1016/j.jtho.2016.11.2215. PubMed PMID: 27865872.

24.       Blagoev KB, Wilkerson J, Burotto M, Kim C, Espinal-Dominguez E, Garcia-Alfonso P, Alimchandani M, Miettinen M, Blanco-Codesido M, Fojo T. Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status. PLoS One. 2017;12(10):e0175484. Epub 2017/10/06. doi: 10.1371/journal.pone.0175484. PubMed PMID: 28981524; PMCID: PMC5628783.

25.       Kim C, Zhang X, Chan AT, Sesso HD, Rifai N, Stampfer MJ, Ma J. Inflammatory biomarkers, aspirin, and risk of colorectal cancer: Findings from the physicians' health study. Cancer Epidemiol. 2016;44:65-70. Epub 2016/08/10. doi: 10.1016/j.canep.2016.07.012. PubMed PMID: 27504605; PMCID: PMC5821121.

26.       Kim C, Rajan A, DeBrito PA, Giaccone G. Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. Transl Lung Cancer Res. 2016;5(6):720-6. Epub 2017/02/06. doi: 10.21037/tlcr.2016.11.06. PubMed PMID: 28149767; PMCID: PMC5233874.

27.       Kim C, Prasad V. Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. Mayo Clin Proc. 2016. Epub 2016/05/30. doi: 10.1016/j.mayocp.2016.02.012. PubMed PMID: 27236424; PMCID: PMC5104665.

28.       Prasad V, Kim C, Burotto M, Vandross A. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. JAMA Intern Med. 2015;175(8):1389-98. Epub 2015/06/23. doi: 10.1001/jamainternmed.2015.2829. PubMed PMID: 26098871.

29.       Kim C, Prasad V. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. JAMA Intern Med. 2015;175(12):1992-4. Epub 2015/10/27. doi: 10.1001/jamainternmed.2015.5868. PubMed PMID: 26502403.

30.       Kim C, Economou S, Amatruda TT, Martin JC, Dudek AZ. Prognostic significance of microscopic tumor burden in sentinel lymph node in patients with cutaneous melanoma. Anticancer Res. 2015;35(1):301-9. Epub 2015/01/01. PubMed PMID: 25550564.

31.       Gummadi T, Zhang BY, Valpione S, Kim C, Kottschade LA, Mittapalli RK, Chiarion-Sileni V, Pigozzo J, Elmquist WF, Dudek AZ. Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. Melanoma Res. 2015;25(1):75-9. Epub 2014/11/27. doi: 10.1097/CMR.0000000000000133. PubMed PMID: 25426645.

32.       Kim DH, Kim C, Ding EL, Townsend MK, Lipsitz LA. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension. 2013;62(1):27-32. Epub 2013/05/30. doi: 10.1161/HYPERTENSIONAHA.113.01453. PubMed PMID: 23716587; PMCID: PMC3729220.

33.       Paik KH, Lee MK, Jin DK, Kang HW, Lee KH, Kim AH, Kim C, Lee JE, Oh YJ, Kim S, Han SJ, Kwon EK, Choe YH. Marked suppression of ghrelin concentration by insulin in Prader-willi syndrome. J Korean Med Sci. 2007;22(2):177-82. Epub 2007/04/24. doi: 10.3346/jkms.2007.22.2.177. PubMed PMID: 17449920; PMCID: PMC2693578.


Reviews or editorials in refereed journals

1.         Jonna S, Reuss JE, Kim C, Liu SV. Oral Chemotherapy for Treatment of Lung Cancer. Frontiers in Oncology. 2020;10:793.

2.         Friedlaender A, Kim C, Addeo A. Rethinking the optimal duration of immune checkpoint inhibitors in non-small cell lung cancer throughout the COVID-19 pandemic. Frontiers in Oncology. 2020;10:862.

3.         Kim C, Liu S. First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward. Oxford University Press; 2019.

4.         Kim C, Giaccone G. Precision oncology in non-small-cell lung cancer: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(6):348-9. Epub 2018/03/31. doi: 10.1038/s41571-018-0008-0. PubMed PMID: 29599475.

5.         Kim C, Giaccone G. MEK inhibitors under development for treatment of non-small-cell lung cancer. Expert Opin Investig Drugs. 2018;27(1):17-30. Epub 2017/12/09. doi: 10.1080/13543784.2018.1415324. PubMed PMID: 29216787.

6.         Kim C, Giaccone G. The role of immune checkpoint blockade for treatment of thymic epithelial tumors—a delicate balance between efficacy and side effects2018.

7.         Kim C, Hoang CD, Kesarwala AH, Schrump DS, Guha U, Rajan A. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(2):179-93. Epub 2016/10/27. doi: 10.1016/j.jtho.2016.10.012. PubMed PMID: 27780780.

8.         Rajan A, Kim C, Heery CR, Guha U, Gulley JL. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother. 2016;12(9):2219-31. Epub 2016/05/03. doi: 10.1080/21645515.2016.1175694. PubMed PMID: 27135835; PMCID: PMC5027703.

9.         Kim C, Giaccone G. Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design. Ann Transl Med. 2016;4(23):466. Epub 2017/01/17. doi: 10.21037/atm.2016.11.48. PubMed PMID: 28090522; PMCID: PMC5220042.

Ratings and reviews

  • Provider explained things understandably

  • Provider listened carefully

  • Provider knew medical history

  • Provider showed respect

  • Provider spent enough time with patient

  • Jan 19, 2023

    Dr Kim is the best!

  • Dec 15, 2022

    Dr Kim always gives me the details of my illness and makes me aware of my treatment options.

  • Dec 12, 2022

    Physician very attentive to what I had to say.